BD (NYSE:BDX) announced today that it completed the enrollment of the first patient in a trial of its Liverty TIPS stent graft.
Franklin Lakes, New Jersey-based BD’s ARCH FDA investigational device exemption (IDE) study evaluates the safety and effectiveness of Liverty. The global, prospective, multi-center, single-arm clinical study looks at the investigational device in the treatment of complications from portal hypertension.
It will include 175 patients across up to 40 clinical study sites in the U.S. and Europe. The study includes follow-up for all treated patients at various points after treatment, starting at one month and ending at 24 months.
Get the full story at our sister site, Medical Tubing & Extrusion.
